Skip to main content
Publications
Tam S, Neslund-Dudas C, Barrett AM, Barrow LCJ, Fridman I, Kinlaw AC, Puviindran P, Royce TJ, Smith AB, Stein JN, Wood WA, Lafata JE. The perceived usability of virtual visits among black adults' receiving oncology care: a qualitative analysis. Oncologist. 2024 Feb 2;29(2):e237-47. doi: 10.1093/oncolo/oyad260
Bergerot C, Young Rha S, Pal S, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Lyun Lee J, Sunela K, Ciuleanu T, Heng D, Glen H, Wang J, Bennett L, Pan J, O'Hara K, Puente J. Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma. Oncologist. 2023 Jan 18;28(1):59-71. doi: 10.1093/oncolo/oyac142
Auclair D, Mansfield C, Fiala MA, Chari A, Cole CE, Kaufman JL, Orloff GJ, Siegel DS, Zonder JA, Mange B, Yesil J, Dalal M, Mikhael JR. Preferences and priorities for relapsed multiple myeloma treatments among patients and caregivers in the United States. Patient Prefer Adherence. 2022 Mar 1;2022(16):573-85. doi: 10.2147/PPA.S345906
Ilomaki J, Bell JS, Chan EW, Tolppanen A-M, Luo H, Wei L, Lai EC, Shin J-U, De Paoli G, Pajouheshnia R, Ho FK, Reynolds L, Lau KK, Crystal S, Lau WCY, Man KKC, Brauer R, Chan AYL, Shen C-Y, Kim JH, Lum TYS, Hartikainen S, Koponen M, Rooke E, Bazelier M, Klungel O, Setoguchi S, Pell JP, Cook S, Wong ICK. Application of healthcare 'big data' in CNS drug research: the example of the neurological and mental health global epidemiology network (NeuroGEN). CNS Drugs. 2020 Sep;34(9):897-913. doi: 10.1007/s40263-020-00742-4
Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R, Young P, Cappelleri JC, Brown TM, Ervin C, Hsu M-A, Fallon L. Treatment mode preferences in psoriatic arthritis: a qualitative multi-country study. Patient Prefer Adherence. 2020 Jun 8;2020(14):949-61. doi: 10.2147/PPA.S242336
Taylor PC, Betteridge N, Brown TM, Woolcott J, Kivitz AJ, Zerbini C, Whalley D, Olayinka-Amao O, Chen C, Dahl P, Ponce de Leon D, Gruben D, Fallon L. Treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making. Patient Prefer Adherence. 2020 Jan 20;14:119-31. doi: 10.2147/PPA.S220714
Garcia-Albeniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective biomarker study in advanced RAS wild‐type colorectal cancer: POSIBA Trial (GEMCAD 10‐02). Oncologist. 2019 Nov;24(11):e1115-22. doi: 10.1634/theoncologist.2018-0728
Pladevall-Vila M, Pottegard A, Schink T, Reutfors J, Morros R, Poblador-Plou B, Timmer A, Forns J, Hellfritzsch M, Reinders T, Hagg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Hallas J, Brandt L, Cortes J, Aguado J, Perlemuter G, Falissard B, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: a cohort and nested case-control study using automated health data sources. CNS Drugs. 2019 Apr;33(4):383-95. doi: 10.1007/s40263-019-00611-9
Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J, Low E, Moulon I, Mavris M, Salmonsson T, Flores B, Hillege H, Pignatti F. Individual trade‐offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma. Oncologist. 2018 Jan;23(1):44-51. doi: 10.1634/theoncologist.2017-0257